NCT05521087 2025-06-22
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
Phase 1 Withdrawn
Clinical Trials
20 trialsNCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05934097 2023-07-06
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
Phase 1 Withdrawn
NCT04974996 2022-03-29
LOTIS-8
ADC Therapeutics S.A.
Phase 1 Withdrawn
NCT04448834 2022-03-02
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
Duke University
Phase 2 Withdrawn
NCT03851081 2022-01-28
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT01415765 2019-12-17
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT02228512 2018-08-31
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT00900445 2018-08-07
Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia
Children's Oncology Group
Withdrawn
NCT00983944 2017-11-30
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02595242 2017-05-23
Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Withdrawn
NCT00513188 2016-12-15
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
University of Miami
Phase NA Withdrawn
NCT02861040 2016-12-15
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Northwestern University
Phase 1 Withdrawn
NCT01539174 2016-03-03
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00003273 2015-12-03
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NYU Langone Health
Phase 2 Withdrawn
NCT00004039 2015-08-19
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Hoag Memorial Hospital Presbyterian
Phase 2 Withdrawn
NCT00334867 2013-06-28
Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma
Children's Oncology Group
Phase 3 Withdrawn
NCT00734773 2012-05-18
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
Northwestern University
Phase EARLY_PHASE1 Withdrawn
NCT00110006 2010-06-11
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase NA Withdrawn